Ligand Pharma (LGND) Pursuing Plans for OmniAb to Become a Standalone Public Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Ligand Pharma (LGND) Pursuing Plans for OmniAb to Become a Standalone Public Company

Ligand Pharma (LGND) Tops Q3 EPS by 54c

November 9, 2021 4:41 PM EST

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.58, $0.54 better than the analyst estimate of $1.04. Revenue for the quarter came in at $64.8 million versus the consensus estimate of $55.65 million.

GUIDANCE:

Ligand Pharma sees FY2021 EPS of $5.80-$6.05, versus the consensus of... More